Completed PHASE4 INTERVENTIONAL 4-arm NCT00153062

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis

Sponsor: Bayer

Conditions Stroke

Interventions Aggrenox Aggrenox placebo Clopidogrel Clopidogrel placebo Micardis Micardis placebo

Updated 8 times since 2017 Last updated: Apr 22, 2014 Started: Aug 31, 2003 Primary completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00153062, this PHASE4 trial focuses on Stroke and remains completed. Sponsored by Bayer, it has been updated 8 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE4
Sep 2025 — Dec 2025 [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Boehringer Ingelheim
GlaxoSmithKline

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aalst, Belgium , Aarhuc C, Denmark , Aarhus C, Denmark , Abington, United States , Adachi-ku, Tokyo, Japan , Akashi, Hyogo, Japan , Ako, Hyogo, Japan , Akron, United States , Albany, United States and 506 more locations